UPDATE 1-Argentina Merval index to shrink to 28 companies in Q2
BUENOS AIRES, March 28 (Reuters) - Argentina's benchmark Merval stock index will shrink to 28 component companies in the second quarter, down from 31
Read moreMon, 24th May 2010 13:42
BUENOS AIRES, March 28 (Reuters) - Argentina's benchmark Merval stock index will shrink to 28 component companies in the second quarter, down from 31
Read moreBUENOS AIRES, March 28 (Reuters) - Argentina's benchmark Merval stock index will shrink to 28 component companies in the second quarter, down from 31
Read moreLONDON (Alliance News) - Biotechnology firm ValirX PLC said Tuesday its VAL201 therapeutic compound has been granted a patent in the US.VAL201, which is currently in is
Read moreLONDON (Alliance News) - Life sciences firm ValiRx PLC said on Monday YA II CD Ltd has cut its stake in the company to below 3%.Prior to last Thursday's YA II CD a
Read more(ShareCast News) - Clinical stage biotechnology company ValiRx announced positive results in its VAL201 personalised Phase l/II prostate cancer study on Wednesday, adding that with accumulation of safety and tolerability data there is also evidence of disease stabilisation on CT imaging and reductio
Read more(ShareCast News) - Life science company focused on clinical stage cancer therapeutic development, ValiRx, updated the market on the clinical development of its novel cancer treatment drug, VAL401. The AIM-traded firm said ValiSeek, the joint venture between ValiRx and Tangent Reprofiling, was formed
Read more(ShareCast News) - Lifesciences company ValiRx reported on a "significant year" on Thursday, talking up its capital restructure and technical advancements in the 2015 calendar year. The AIM-traded firm, which focuses on cancer therapeutics and diagnostics for personalised medicine, said its Phase I/
Read more